[go: up one dir, main page]

RU2003125142A - METHOD OF PERFUOROAN USE - Google Patents

METHOD OF PERFUOROAN USE Download PDF

Info

Publication number
RU2003125142A
RU2003125142A RU2003125142/14A RU2003125142A RU2003125142A RU 2003125142 A RU2003125142 A RU 2003125142A RU 2003125142/14 A RU2003125142/14 A RU 2003125142/14A RU 2003125142 A RU2003125142 A RU 2003125142A RU 2003125142 A RU2003125142 A RU 2003125142A
Authority
RU
Russia
Prior art keywords
perfuoroan
perftoran
dose
multiplicity
onset
Prior art date
Application number
RU2003125142/14A
Other languages
Russian (ru)
Inventor
Сергей Валентинович Максимишин (RU)
Сергей Валентинович Максимишин
Валерий Васильевич Семченко (RU)
Валерий Васильевич Семченко
Виктор Васильевич Мороз (RU)
Виктор Васильевич Мороз
Николай Анатольевич Новицкий (RU)
Николай Анатольевич Новицкий
Original Assignee
Сергей Валентинович Максимишин (RU)
Сергей Валентинович Максимишин
Валерий Васильевич Семченко (RU)
Валерий Васильевич Семченко
Виктор Васильевич Мороз (RU)
Виктор Васильевич Мороз
Николай Анатольевич Новицкий (RU)
Николай Анатольевич Новицкий
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сергей Валентинович Максимишин (RU), Сергей Валентинович Максимишин, Валерий Васильевич Семченко (RU), Валерий Васильевич Семченко, Виктор Васильевич Мороз (RU), Виктор Васильевич Мороз, Николай Анатольевич Новицкий (RU), Николай Анатольевич Новицкий filed Critical Сергей Валентинович Максимишин (RU)
Priority to RU2003125142/14A priority Critical patent/RU2003125142A/en
Publication of RU2003125142A publication Critical patent/RU2003125142A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (1)

Способ применения перфторана, заключающийся во внутривенном капельном введении препарата в дозе, со скоростью и кратностью, обеспечивающими лечебный эффект, отличающийся тем, что перфторан вводят в дозе 6...8 мл/кг массы тела больного, со скоростью 20...30 мл/кг в час, трехкратно, на первые, третьи и пятые сутки, причем первое введение осуществляют не позднее 6-ти часов от начала заболевания.The method of using perftoran, which consists in the intravenous drip of the drug in a dose, at a speed and multiplicity, providing a therapeutic effect, characterized in that perftoran is administered at a dose of 6 ... 8 ml / kg of patient’s body weight, at a rate of 20 ... 30 ml / kg per hour, three times, on the first, third and fifth days, and the first injection is carried out no later than 6 hours from the onset of the disease.
RU2003125142/14A 2003-08-11 2003-08-11 METHOD OF PERFUOROAN USE RU2003125142A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2003125142/14A RU2003125142A (en) 2003-08-11 2003-08-11 METHOD OF PERFUOROAN USE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2003125142/14A RU2003125142A (en) 2003-08-11 2003-08-11 METHOD OF PERFUOROAN USE

Publications (1)

Publication Number Publication Date
RU2003125142A true RU2003125142A (en) 2005-02-20

Family

ID=35218344

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003125142/14A RU2003125142A (en) 2003-08-11 2003-08-11 METHOD OF PERFUOROAN USE

Country Status (1)

Country Link
RU (1) RU2003125142A (en)

Similar Documents

Publication Publication Date Title
JP2005520778A5 (en)
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
CA2601715A1 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
JP2002522485A5 (en)
RU2007132181A (en) ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR
MXPA03006217A (en) Spaced drug delivery system.
NO20043871L (en) Controlled release drug formulations containing a carrier peptide
MXPA05012810A (en) Memantine oral dosage forms.
JP2006514681A5 (en)
JP2002530353A5 (en)
RU2007119545A (en) PEGLIATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH ECTEINASCIDIN 743 (ECTEINESCIDIN 743)
RU2005131938A (en) METHOD FOR NORMALIZATION OF URINAL DISORDER IN VIOLATION OF THE KIDNEY FUNCTION
RU2002117537A (en) A method for treating the effects of tissue hypoxia in critically ill patients
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
RU2003125142A (en) METHOD OF PERFUOROAN USE
RU2004112422A (en) ROUVASTATIN IN PREDEDENTIONAL CONDITIONS
JP2005529152A5 (en)
ATE446309T1 (en) CAPILLARY RESISTANCE IMPROVEMENT PEPTIDE SUBSTANCE, PHARMACEUTICAL COMPOSITION BASED THEREOF AND METHOD FOR USE THEREOF
JP2002529515A5 (en)
RU2002113978A (en) A method of stimulating motor activity of the intestine
RU2002101630A (en) A method of treating endometritis in cows
RU2000110690A (en) METHOD OF ANTIBIOTIC THERAPY
RU2002109173A (en) A method for the treatment of degenerative diseases of the retina
RU2006137657A (en) USE OF CAMPTOTECINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES USING A FIXED DOSE TREATMENT SCHEME
Brogard et al. Biliary elimination of cefotiam, an experimental and clinical study

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20070109